Overview

A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Areteia Therapeutics
Treatments:
Pramipexole